← back to search
Li Cp
Guangxi Medical University
· CN
Area of research
Oncology · Biotechnology
Research interest
Research interests include Medicine, Erlotinib, Gemcitabine, Rash, Pancreatic cancer, and Internal medicine.
h-index
—
citations
48
works
2
NIH funding
—
primary concept
—
email
✉ Find email ↗
Recent publications
Effect of polyethylene Glycol Loxenatide (long-acting GLP-1RA) on lipid, glucose levels and weight in type 2 diabetes mellitus patients with obesity.
PubMed
2022
cited by
8
position: middle
doi
Dose escalation to rash for erlotinib plus gemcitabine for metastatic pancreatic cancer: the phase II RACHEL study
British Journal of Cancer
2014
cited by
40
position: middle
doi
Grants
No grants ingested yet.
Frequent collaborators
Eric Van Cutsem
· KU Leuven
1
papers (2014–2014)
Giuseppe Aprile
· University of Udine
1
papers (2014–2014)
Xue Meng
· South China Agricultural University
1
papers (2014–2014)
—
·
1
papers (2014–2014)
Wu Zz
· Nanchang University
1
papers (2022–2022)
X-Y Li
· Guangzhou University of Chinese Medicine
1
papers (2022–2022)
Zhang Cy
· Shanghai University
1
papers (2022–2022)
—
·
1
papers (2014–2014)
Tudor–Eliade Ciuleanu
· Iuliu Hațieganu University of Medicine and Pharmacy
1
papers (2014–2014)
Malcolm J. Moore
· University Health Network
1
papers (2014–2014)
Salomon M. Stemmer
· Tel Aviv University
1
papers (2014–2014)
—
·
1
papers (2014–2014)
—
·
1
papers (2022–2022)
—
·
1
papers (2014–2014)
Elżbieta Nowara
· Amgen (United States)
1
papers (2014–2014)
—
·
1
papers (2022–2022)
—
·
1
papers (2022–2022)
—
·
1
papers (2022–2022)
Barbara Klughammer
· Roche (Switzerland)
1
papers (2014–2014)
—
·
1
papers (2014–2014)